Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Compugen ( (CGEN) ) is now available.
On December 16, 2025, Compugen Ltd. amended its license agreement with AstraZeneca, monetizing a portion of future royalties from rilvegostomig for an upfront payment of $65 million and a potential milestone payment of $25 million. This strategic transaction strengthens Compugen’s financial position, extending its cash runway to 2029, allowing funds to be allocated towards advancing its innovative immuno-oncology pipeline, including internal and partnered programs. Retaining the majority of future royalties, Compugen preserves long-term upside from the potential success of rilvegostomig, developed by AstraZeneca as a promising cancer immunotherapy drug, which is undergoing robust Phase 3 trials across various types of cancer.
The most recent analyst rating on (CGEN) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Compugen stock, see the CGEN Stock Forecast page.
Spark’s Take on CGEN Stock
According to Spark, TipRanks’ AI Analyst, CGEN is a Neutral.
Compugen’s overall stock score is primarily influenced by its financial performance and technical analysis. The company’s strategic partnerships and potential future milestones provide some optimism, but current financial challenges and valuation concerns weigh heavily on the score.
To see Spark’s full report on CGEN stock, click here.
More about Compugen
Compugen Ltd. is a clinical-stage therapeutic discovery and development company specializing in cancer immunotherapies powered by its AI/ML predictive computational discovery platform, Unigen™. The company develops innovative immuno-oncology drug candidates including COM902, an anti-TIGIT antibody, and COM701, an anti-PVRIG antibody, with programs targeting biological pathways to activate the immune system against cancer. Headquartered in Israel, Compugen’s shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.
Average Trading Volume: 398,776
Technical Sentiment Signal: Strong Sell
Current Market Cap: $139.4M
For detailed information about CGEN stock, go to TipRanks’ Stock Analysis page.